14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MXCT vs BWAY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas BWAY carries 31.8/100 (SELL) at $8.48 (17.0x Forward P/E, 12.5% operating margin).
Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. BWAY 31.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -85.5% operating margin) and revenue trajectory (+35.4% vs. +48.7% YoY).
Defensive Composite Rating Caution: Although BWAY compares more favorably head-to-head, both MXCT (41.7/100 SELL) and BWAY (31.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile BWAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MXCT vs BWAY. Trailing 12-month operating profitability (MXCT -85.5% vs BWAY 12.5%) and valuation multiples (MXCT N/M vs BWAY 17.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $351.4M market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment62.8% of Rev ($68M)
90D Engineering Disclosures0 Published
Investor FAQ MXCT vs BWAY Key Questions & Quantitative Answers
As of Nov 20, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas BWAY carries 31.8/100 (SELL) at $8.48 (17.0x Forward P/E, 12.5% operating margin). Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. BWAY 31.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -85.5% operating margin) and revenue trajectory (+35.4% vs. +48.7% YoY). Defensive Composite Rating Caution: Although BWAY compares more favorably head-to-head, both MXCT (41.7/100 SELL) and BWAY (31.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile BWAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BWAY leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with BWAY at +35.4% YoY revenue growth and +59.8% YoY earnings growth on $108M TTM revenue (75.3% gross margin, 12.5% operating margin). On trailing 12-month operating scale, MXCT generates $34M in USD-normalized revenue versus $108M for BWAY. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 62.8% of Rev ($68M) (0 disclosures) for BWAY.
BWAY screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas BWAY trades at 17.0x Forward P/E, 36.4x Trailing P/E, N/M PEG, and 3.3x EV/Revenue (14.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus BWAY (12.8% ROE) capital efficiency.
In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, BWAY carries 111.0% implied volatility (77th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.